OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 130 filers reported holding OCULAR THERAPEUTIX INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $105,818 | -94.2% | 33,700 | -90.5% | 0.00% | -100.0% |
| Q2 2023 | $1,827,672 | +12.1% | 354,200 | +14.5% | 0.01% | +25.0% |
| Q1 2023 | $1,630,538 | +80.4% | 309,400 | -3.8% | 0.00% | +33.3% |
| Q4 2022 | $903,977 | -38.8% | 321,700 | -9.7% | 0.00% | -25.0% |
| Q3 2022 | $1,478,000 | -5.5% | 356,200 | -8.5% | 0.00% | 0.0% |
| Q2 2022 | $1,564,000 | -53.9% | 389,100 | -43.2% | 0.00% | -55.6% |
| Q1 2022 | $3,391,000 | -38.5% | 685,100 | -13.4% | 0.01% | -35.7% |
| Q4 2021 | $5,512,000 | -48.8% | 790,800 | -26.5% | 0.01% | -50.0% |
| Q3 2021 | $10,763,000 | -36.1% | 1,076,300 | -9.3% | 0.03% | -36.4% |
| Q2 2021 | $16,833,000 | -16.1% | 1,187,100 | -2.9% | 0.04% | -20.0% |
| Q1 2021 | $20,058,000 | -9.0% | 1,222,300 | +14.8% | 0.06% | -6.8% |
| Q4 2020 | $22,048,000 | +791.5% | 1,065,100 | +227.7% | 0.06% | +742.9% |
| Q3 2020 | $2,473,000 | +777.0% | 325,000 | +858.7% | 0.01% | +600.0% |
| Q2 2020 | $282,000 | – | 33,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $19,223 | 100.00% |
| Opaleye Management Inc. | 6,468,000 | $20,309,520 | 6.61% |
| DELTEC ASSET MANAGEMENT LLC | 2,061,797 | $6,474,043 | 1.48% |
| Endurant Capital Management LP | 353,707 | $1,110,640 | 1.00% |
| SECTORAL ASSET MANAGEMENT INC | 969,350 | $3,043,759 | 0.59% |
| NOTTINGHAM ADVISORS, INC. | 194,266 | $609,995 | 0.09% |
| Covestor Ltd | 37,404 | $117 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 233,582 | $733 | 0.06% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 342,111 | $1,074,229 | 0.03% |
| Polar Asset Management Partners Inc. | 263,763 | $828,216 | 0.02% |